Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Immuno Oncology And Immuno Equipment Supplied In Usa
27 equipment items found
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
CB-1158 dihydrochloride (INCB01158 dihydrochloride) is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM forrecombinant human arginase 1 andrecombinant human arginase 2, respectively. Immuno-oncology ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
elociT™ is our unique mouse technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens. Regeneron uses this technology as part of its efforts to discover and develop novel immuno-oncology therapeutic candidates, including combination approaches and to assist our collaborators in producing fully human therapeutic ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
T cell engineering with TCRs is a growing area of immuno-oncology with recent breakthroughs in clinical settings. The T-Cure approach involves identifying and isolating a high avidity TCR which specifically recognizes an intracellular or cell-surface target in solid tumors. This TCR is then typically introduced into a viral vector that can deliver the TCR into ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE800 is an orally administered rationally-defined bacterial consortium immuno-oncology candidate. VE800 consists of 11 clonal human commensal bacteria strains manufactured under cGMP conditions and selected for their ability to induce CD8+ T cells, potentiate the immune system’s attack of tumors and enhance the effects of checkpoint ...
Manufactured by:Orgenesis Inc. based inGermantown, MARYLAND (USA)
Our POCare Platform overcomes conventional processing challenges by enabling sterile, scalable onsite processing for a pipeline of advanced ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Our approach has demonstrated monotherapy activity, reducing tumor volume in a mouse xenograft model of renal cell carcinoma. Recent high profile publications provide preclinical in vivo rationale for monotherapy and combinations with immuno-oncology agents, kinase inhibitors, and chemotherapy. Optimization of oral lead compounds is ...
Manufactured by:Quanterix Corporation based inBillerica, MASSACHUSETTS (USA)
The Quanterix SP-X Imaging and Analysis System is a complete benchtop system that offers true multiplex detection at both acute and baseline levels. For the first time, oncology and immuno-oncology researchers and others who rely on multiplexing capabilities have an easy-to-use platform to help optimize workflows, speed up their research and ...
by:BICO - The Bio Convergence Company based inBoston, MASSACHUSETTS (USA)
The high-throughput, fully automated biodispensing solution that leverages BIOPOD (bioprinting on demand) technology with pre-set and pre-validated protocols to bring the power of 3D cell biology to your ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, which is advantageous when bystander cells are cancerous but toxic if the cytotoxic drug is able to enter adjacent healthy cells. The DolaLock payload ...
Manufactured by:BioXcel Therapeutics, Inc. based inNew Haven, CONNECTICUT (USA)
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to induction of IL-18 and IL-1ß, bridging innate & adaptive immunity. BXCL701 is currently being developed for the treatment of aggressive forms of prostate cancer and ...
Manufactured by:ENB Therapeutics based inNew York, NEW YORK (USA)
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. Activated T cells are then able to infiltrate the tumor and kill ...
Manufactured by:Theriva Biologics, Inc., formely known as ynthetic Biologics, Inc. based inRockville, MARYLAND (USA)
Building on the clinical advancement of VCN-01, Theriva developed the Albumin Shield™ technology to protect oncolytic viruses from circulating anti-oncolytic virus antibodies after systemic administration. We anticipate that this technology will enable multiple oncolytic virus doses to be administered in therapeutic cycles to treat particularly refractory ...
Manufactured by:BiomX based inNess Ziona, ISRAEL
BiomX develops phage cocktails (or combinations) that target and kill specific pathogenic bacteria. Our phage cocktails, which are optimized through algorithms and experimental validation (in-vitro and in-vivo), contain multiple natural and/or engineered phage. The phage are selected to have complementary functions such as wide target bacterial host range and the ability to avoid the development ...
Manufactured by:NanoString based inSeattle, WASHINGTON (USA)
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler ...
by:Oncimmune Holdings PLC based inNottingham, UNITED KINGDOM
Oncimmune’s proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers that can help stratify patients in multiple cancer indications and with different autoimmune ...
Manufactured by:Veracyte based inMarseille Cedex 9, FRANCE
Veracyte offers a unique multiplex tissue imaging and analysis approach combining multiple technologies perfectly adapted to the comprehensive characterization of the tumor microenvironment. ...
Manufactured by:AllCells based inAlameda, CALIFORNIA (USA)
Leukopaks are enriched leukapheresis products collected from healthy and consenting donors using the Spectra Optia® Apheresis System following an IRB-approved protocol. Leukopaks typically contain up to 50% T cells, 20% monocytes, 10% B cells, 10% NK cells, 3% granulocytes, and 3% hematocrit. Leukapheresis results in high yields of single-donor mononuclear cells (MNCs) compared to ...
Manufactured by:Prellis Biologics, Inc. based inSan Francisco, CALIFORNIA (USA)
EXIS Human Immune Response: Prellis utilizes its proprietary holographic printing technology to engineer 3D printed lymph node organoids (LNOs) that recreates the human immunobiology in vitro allowing direct access to a fully functional human immune system. EXIS is a powerful and scalable platform with applications in antibody discovery (human and llama), immunogenicity evaluation, and in vitro ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC ...